EP3655427A1 — Bifunctional compounds
Assigned to Novo Nordisk AS · Expires 2020-05-27 · 6y expired
What this patent protects
The present invention provides compounds useful in the treatment of diabetes, weight loss and / or cardiovascular risk reduction. The compounds are bifunctional and are therefore suitable as a single treatment for patients who may benefit from treatment with both a GLP-1 receptor…
USPTO Abstract
The present invention provides compounds useful in the treatment of diabetes, weight loss and / or cardiovascular risk reduction. The compounds are bifunctional and are therefore suitable as a single treatment for patients who may benefit from treatment with both a GLP-1 receptor agonist and a PCSK9 inhibitor.
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.